NO174506B - Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser - Google Patents
Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser Download PDFInfo
- Publication number
- NO174506B NO174506B NO854321A NO854321A NO174506B NO 174506 B NO174506 B NO 174506B NO 854321 A NO854321 A NO 854321A NO 854321 A NO854321 A NO 854321A NO 174506 B NO174506 B NO 174506B
- Authority
- NO
- Norway
- Prior art keywords
- hal
- solution
- compound
- formula
- quinoline
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 238000000034 method Methods 0.000 title claims description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 125000001424 substituent group Chemical group 0.000 claims abstract description 9
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 8
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 150000002367 halogens Chemical class 0.000 claims abstract description 6
- 125000005843 halogen group Chemical group 0.000 claims abstract 2
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 150000001721 carbon Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims description 4
- 230000005494 condensation Effects 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- PUPULQCZPABFPH-UHFFFAOYSA-N 2-[3-(quinolin-2-ylmethoxy)phenyl]heptan-2-ol Chemical compound CCCCCC(C)(O)C1=CC=CC(OCC=2N=C3C=CC=CC3=CC=2)=C1 PUPULQCZPABFPH-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000005493 quinolyl group Chemical group 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 2
- PIESJVRMEIITQU-UHFFFAOYSA-N 7-phenoxy-2-[3-(quinolin-2-ylmethoxy)phenyl]heptan-2-ol Chemical compound C=1C=CC(OCC=2N=C3C=CC=CC3=CC=2)=CC=1C(O)(C)CCCCCOC1=CC=CC=C1 PIESJVRMEIITQU-UHFFFAOYSA-N 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 4
- 125000003545 alkoxy group Chemical group 0.000 abstract description 2
- 125000001589 carboacyl group Chemical group 0.000 abstract description 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract description 2
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 239000011593 sulfur Substances 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- 239000012267 brine Substances 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 11
- 239000003039 volatile agent Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 150000002576 ketones Chemical class 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- DDEAEWMDOSXKBX-UHFFFAOYSA-N 2-(chloromethyl)quinoline Chemical compound C1=CC=CC2=NC(CCl)=CC=C21 DDEAEWMDOSXKBX-UHFFFAOYSA-N 0.000 description 6
- IAVREABSGIHHMO-UHFFFAOYSA-N 3-hydroxybenzaldehyde Chemical compound OC1=CC=CC(C=O)=C1 IAVREABSGIHHMO-UHFFFAOYSA-N 0.000 description 6
- KGIJOOYOSFUGPC-CABOLEKPSA-N 5-HETE Natural products CCCCC\C=C/C\C=C/C\C=C/C=C/[C@H](O)CCCC(O)=O KGIJOOYOSFUGPC-CABOLEKPSA-N 0.000 description 6
- KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000007818 Grignard reagent Substances 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 150000004795 grignard reagents Chemical class 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 229910000039 hydrogen halide Inorganic materials 0.000 description 3
- 239000012433 hydrogen halide Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- -1 lithium aluminum hydride Chemical compound 0.000 description 3
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- IEBXKAMPDSGJFA-UHFFFAOYSA-N 1-(3-hydroxyphenyl)-2,2-dimethylhexan-1-one Chemical compound CCCCC(C)(C)C(=O)C1=CC=CC(O)=C1 IEBXKAMPDSGJFA-UHFFFAOYSA-N 0.000 description 2
- LHFXTLCYZARWLB-UHFFFAOYSA-N 1-[3-(quinolin-2-ylmethoxy)phenyl]hexan-1-one Chemical compound CCCCCC(=O)C1=CC=CC(OCC=2N=C3C=CC=CC3=CC=2)=C1 LHFXTLCYZARWLB-UHFFFAOYSA-N 0.000 description 2
- WDETYCRYUBGKCE-UHFFFAOYSA-N 2-(chloromethyl)quinolin-1-ium;chloride Chemical compound Cl.C1=CC=CC2=NC(CCl)=CC=C21 WDETYCRYUBGKCE-UHFFFAOYSA-N 0.000 description 2
- WNGRHTGNGQSCTL-UHFFFAOYSA-N 5-bromopentoxybenzene Chemical compound BrCCCCCOC1=CC=CC=C1 WNGRHTGNGQSCTL-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 239000004533 oil dispersion Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- IBODDUNKEPPBKW-UHFFFAOYSA-N 1,5-dibromopentane Chemical compound BrCCCCCBr IBODDUNKEPPBKW-UHFFFAOYSA-N 0.000 description 1
- YUWMKUYZYSWEAH-UHFFFAOYSA-N 1-(3-hydroxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=CC=CC(O)=C1 YUWMKUYZYSWEAH-UHFFFAOYSA-N 0.000 description 1
- GNQQKIMXEGMXHV-UHFFFAOYSA-N 1-[3-[[[3-(1-hydroxyhexyl)phenyl]-phenylmethoxy]-phenylmethyl]phenyl]hexan-1-ol Chemical compound CCCCCC(O)C1=CC=CC(C(OC(C=2C=CC=CC=2)C=2C=C(C=CC=2)C(O)CCCCC)C=2C=CC=CC=2)=C1 GNQQKIMXEGMXHV-UHFFFAOYSA-N 0.000 description 1
- OBPXAMHRBGRFRE-UHFFFAOYSA-N 2,2-dimethyl-1-[3-(quinolin-2-ylmethoxy)phenyl]hexan-1-one Chemical compound CCCCC(C)(C)C(=O)C1=CC=CC(OCC=2N=C3C=CC=CC3=CC=2)=C1 OBPXAMHRBGRFRE-UHFFFAOYSA-N 0.000 description 1
- CTQMCZUHPABXNZ-UHFFFAOYSA-N 2-methyl-1-[3-(quinolin-2-ylmethoxy)phenyl]hexan-1-ol Chemical compound CCCCC(C)C(O)C1=CC=CC(OCC=2N=C3C=CC=CC3=CC=2)=C1 CTQMCZUHPABXNZ-UHFFFAOYSA-N 0.000 description 1
- RGNOMOYQWHWISI-UHFFFAOYSA-N 2-methyl-1-[3-(quinolin-2-ylmethoxy)phenyl]hexan-1-one Chemical compound CCCCC(C)C(=O)C1=CC=CC(OCC=2N=C3C=CC=CC3=CC=2)=C1 RGNOMOYQWHWISI-UHFFFAOYSA-N 0.000 description 1
- UOXWCVKSXDUIIQ-UHFFFAOYSA-N 3,3-dimethyl-7-phenoxy-2-[3-(quinolin-2-ylmethoxy)phenyl]heptan-2-ol Chemical compound C=1C=CC(OCC=2N=C3C=CC=CC3=CC=2)=CC=1C(C)(O)C(C)(C)CCCCOC1=CC=CC=C1 UOXWCVKSXDUIIQ-UHFFFAOYSA-N 0.000 description 1
- WHTOUZVXKPHWMV-UHFFFAOYSA-N 3-(1-hydroxy-6-phenoxyhexyl)phenol Chemical compound C=1C=CC(O)=CC=1C(O)CCCCCOC1=CC=CC=C1 WHTOUZVXKPHWMV-UHFFFAOYSA-N 0.000 description 1
- OEELSOIUBJARFL-UHFFFAOYSA-N 3-(1-hydroxy-6-phenylmethoxyhexyl)phenol Chemical compound C=1C=CC(O)=CC=1C(O)CCCCCOCC1=CC=CC=C1 OEELSOIUBJARFL-UHFFFAOYSA-N 0.000 description 1
- VFFVFTQDHRZVCF-UHFFFAOYSA-N 3-(2-hydroxyheptan-2-yl)phenol Chemical compound CCCCCC(C)(O)C1=CC=CC(O)=C1 VFFVFTQDHRZVCF-UHFFFAOYSA-N 0.000 description 1
- IEFWWMUTPDTSOB-UHFFFAOYSA-N 3-methyl-1-[3-(quinolin-2-ylmethoxy)phenyl]butane-1,3-diol Chemical compound CC(C)(O)CC(O)C1=CC=CC(OCC=2N=C3C=CC=CC3=CC=2)=C1 IEFWWMUTPDTSOB-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- CJTIIENSKNSEFX-UHFFFAOYSA-N 5,5,5-trifluoro-1-(3-hydroxyphenyl)pentan-1-one Chemical compound OC1=CC=CC(C(=O)CCCC(F)(F)F)=C1 CJTIIENSKNSEFX-UHFFFAOYSA-N 0.000 description 1
- BYBTZXMAYSKSNX-UHFFFAOYSA-N 5,5,5-trifluoro-1-[3-(quinolin-2-ylmethoxy)phenyl]pentan-1-one Chemical compound FC(F)(F)CCCC(=O)C1=CC=CC(OCC=2N=C3C=CC=CC3=CC=2)=C1 BYBTZXMAYSKSNX-UHFFFAOYSA-N 0.000 description 1
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 1
- PZLSEUJXKMVYDQ-UHFFFAOYSA-N 6,6,6-trifluoro-1-[3-(quinolin-2-ylmethoxy)phenyl]hexan-1-one Chemical compound FC(F)(F)CCCCC(=O)C1=CC=CC(OCC=2N=C3C=CC=CC3=CC=2)=C1 PZLSEUJXKMVYDQ-UHFFFAOYSA-N 0.000 description 1
- IBWXSCCLJMHENK-UHFFFAOYSA-N 6-phenoxy-1-[3-(quinolin-2-ylmethoxy)phenyl]hexan-1-ol Chemical compound C=1C=CC(OCC=2N=C3C=CC=CC3=CC=2)=CC=1C(O)CCCCCOC1=CC=CC=C1 IBWXSCCLJMHENK-UHFFFAOYSA-N 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000620009 Homo sapiens Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GOPYZMJAIPBUGX-UHFFFAOYSA-N [O-2].[O-2].[Mn+4] Chemical class [O-2].[O-2].[Mn+4] GOPYZMJAIPBUGX-UHFFFAOYSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical group C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- JRQAVOSEAWZPCC-UHFFFAOYSA-N methyl 4-oxo-4-[3-(quinolin-2-ylmethoxy)phenyl]butanoate Chemical compound COC(=O)CCC(=O)C1=CC=CC(OCC=2N=C3C=CC=CC3=CC=2)=C1 JRQAVOSEAWZPCC-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- WHRAMHWTLGRJHH-UHFFFAOYSA-M sodium;3-formylphenolate Chemical compound [Na+].[O-]C1=CC=CC(C=O)=C1 WHRAMHWTLGRJHH-UHFFFAOYSA-M 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/794—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring
- C07C49/796—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
- C07C49/825—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups all hydroxy groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Forbindelser av formel. og salter derav, hvori. Ar! er en nitrogen-,. svovel- eller oxygenheterosyk-lisk ring eller en aromatisk. ring,. Ar er en fenylring eller en. nitrogen-, oxygen- eller svovel-heterosyklisk ring, idet. Ar og A^ eventuelt kan. være substituert,Z er en alkylenkjede som. eventuelt kan inneholde opptil to dobbeltbindinger og som kan være bundet til Ar via et oxygen-, svovel- eller amino-nitrogenatom.N'R'C0Rlacton eller halogen;. Rx er H ellerH,. R 2 er H, lavere alkyl, aryl eller aralkyl;. Rer H, lavere alkyl, lavere alkanoyl, aryl, aralkyl eller substituert aryl, hvori substituenten er halogen, lavere alkyl eller lavere alkoxy,. Rer 0Reller N(R), n = 0 eller 1,. n' = 1-7, og n'' =, 1 eller 2, utviser terapeutisk aktivitet. Fremstilling av forbindelsene er beskrevet.
Description
Foreliggende oppfinnelse angår en analogifremgangsmåte for fremstilling av nye kjemiske forbindelser som utviser verdifull farmasøytisk aktivitet. Nærmere bestemt angår oppfinnelsen fremstilling av nye lipoxygenaseinhibitorforbind-elser som utviser antiinflammatorisk og antiallergisk aktivitet.
Ved foreliggende oppfinnelse fremstilles forbindelser med den generelle formel:
og farmasøytisk akseptable salter derav, hvori Arx er kinolyl, naftyl eller tetrahydronaftyl; Ar er meta-fenylen eller para-fenylen;idet Z er en alkylenkjede inneholdende opptil 10 carbonatomer i hovedkjeden og totalt opptil 12 carbonatomer, og med fra 0-2 dobbeltbindinger, og hvor angitte alkylenkjede kan være bundet til Ar gjennom et oxygenatom, når n' =2 eller 3 er R en substituent uavhengig bundet til et av carbonatomene i Z, utvalgt fra gruppen =0, 0R3, N(R2)2, -CH3 og -C0R4; og når n' =4 til 7 er R en substituent uavhengig bundet til et carbonatom i Z, utvalgt fra gruppen =0, 0R3, N(R2)2, -CH3, -C0R4 og halogen;
med det forbehold at et omegacarbon av Z ikke er disubstituert med =0 og -0R3, og med det forbehold at når n' er 2 og R er -CH3, er -CH3 ikke beliggende på Z-alkylenkjedens terminale carbonatom;
R2 er H, Ci-Cg-alkyl, fenyl eller benzyl;
R3 er H, Ci-Cg-alkyl, C^-Cg-alkanoyl, fenyl, benzyl eller substituert fenyl, hvori substituenten er halogen, C1-C6-alkyl eller C^-Cg-alkoxy;
R4 er 0R2 eller N(R2)2<;>
n' = 2-7.
Alkylenkjedene representert ved Z kan være normale eller forgrenede kjeder, hvori grenene er fortrinnsvis methyl eller ethyl og innbefatter de hvori to slike grupper, f.eks. methyl, er på samme carbonatom. Alkylenkjedene inne-holder fortrinnsvis opptil 8 carbonatomer, enten disse er forgrenede eller normale. Alkylenkjeden kan inneholde opptil to dobbeltbindinger og kan være bundet direkte til A-ringen gjennom et oxygenatom.
Av gruppene som er representative for X i den foregå-ende formel, er spesielt gruppen -CH20- foretrukket.
Analogifremgangsmåten ifølge foreliggende oppfinnelse for fremstilling av forbindelser med formel I er kjennetegnet ved
kondensering av en forbindelse av formel II med en forbindelse av formel III:
hvori
X' er -CH2-Hal og X'' er -0H; eller
X' er -0H og X'' er -CH2Hal; eller
X' er -Hal og X'' er -CH2OH; eller
X' er -CH2OH og X'1 er -Hal; eller
X' er -CH2OH og X' ' er -CH2Hal; eller
X' er -CH2-Hal og X' ' er -CH2OH; eller
X' er -0H og X" er -Hal; eller
X<*> er -Hal og X'' er -0H;
under substitusjonsreaksjonsbetingelser for dannelse av en forbindelse av formel I.
Således kan forbindelsene fremstilles ved for-skjellige syntesemetoder som eksemplifisert ved følgende: 1. Kondensasjon av en forbindelse med formel II
hvori X' er -CH2Hal, -Hal, -0H eller -CH2OH med en forbindelse av formel III
hvori X' ' er -CH2Hal, -Hal, -0H eller -CH2OH via eliminering av X' og X" med en rest Z gjenværende etter kondensasjon. Slike kondensasjonsreaksjoner er kjent og finner sted f.eks.
mellom -CH2Hal og -0H med eliminering av hydrogenhalogenid og dannelse av brogruppen -CH20- mellom de to ringer av det resulterende produkt. Anvendelse av halogen i stedet for -CH2Hal-resulterer i difenyletherstrukturen (hvori X er -0-). Denne reaksjon er kjent som Ullman-ethersyntese.
En variant av denne syntesemetode anvender Grignard-reagenset i stedet for den halogenholdige substituent.
2. Alternativt kan substituenten -Z-(R)n' adderes til forbindelser av formel IV
under anvendelse av klassiske acylerings- eller alkylerings-kondensasjonsreaksjoner, f.eks. et acylerende derivat av en syre med en Friedl-Crafts-katalysator for å tilveiebringe forbindelser hvori
fra hvilke forbindelser, hvori R er forskjellig fra 0, kan fremstilles ved kjente reaksjoner, f.eks. ved reduksjon av carbonyloxygenet til -0H under anvendelse av lithiumalumini-umhydrid og liknende reduksjonsmidler.
De beskrevne reaksjoner utføres under anvendelse av klassiske organiske reaksjoner kjent innen faget. Selvsagt blokkeres fortrinnsvis reaktive grupper, hvis slike er til stede, etter kjente metoder for å unngå konkurrering eller bireaksjoner.
De ovenfor angitte reaksjoner utføres i et organisk løsningsmiddel for de reaktive utgangsmaterialer ved tempe-raturer varierende fra romtemperatur opp til reaksjonsblan-dingens tilbakeløpstemperatur. I kondensasjonsreaksjoner, hvori hydrogenhalogenid dannes, er en hydrogenhalogenid-akseptor, dvs. vanligvis en basisk forbindelse slik som et organisk amin, til stede for å lette reaksjonen. I de reaksjoner hvor en Friedl-Crafts-katalysator anvendes, er aluminiumklorid eller zinkklorid generelt anvendbare.
Sluttproduktene gjenvinnes fra reaksjonsblandingen og renses deretter etter kjente prosedyrer, f.eks. kolonne-kromatografiske teknikker.
Forbindelsene fremstilt ifølge oppfinnelsen inne-holder basisk nitrogen, danner salter med syrer, både organiske og uorganiske. Av særlig verdi er salter med farmasøytisk akseptable syrer, spesielt i doseringsformer basert på vandige systemer hvor den forøkede vannløselighet av saltene er mest fordelaktig. Salter dannet med farmasøytisk uakseptable syrer, er også anvendbare ved isolering og rensing av de basiske, nitrogenholdige nye forbindelser. Salter innbefatter de som dannes med saltsyre, svovelsyre, salpetersyre, perklorsyre, benzensulfonsyre, toluensulfonsyre, fosforsyre, eddiksyre, eplesyre, malonsyre, vinsyre og liknende syrer.
Forbindelsene fremstilt ifølge oppfinnelsen eksisterer også i stereoisomere former på grunn av nærvær av asymmetriske sentra i molekylet, spesielt i gruppen -Z(R)n. og i kjeden -X- (hvori R^^ er forskjellig fra H), eller i andre deler av molekylet. Foreliggende oppfinnelse tar i betraktning stereoisomerer individuelt eller i blandinger, eller som den racemiske forbindelse. De individuelle stereoisomerer kan erholdes ved standard oppløsningsprosedyrer kjent innen faget, eller ved stereospesifikke synteser.
Forbindelsene fremstilt ifølge oppfinnelsen kan ad-ministreres til verten i et utall former tilpasset til den valgte administreringsmåte, dvs. oralt eller parenteralt.
De etterfølgende eksempler- illustrerer oppfinnelsen.
Eksempel 1
2-[3-( l- hydroxy- 2- methylhexyl)- fenoxymethyl]- kinolin A. En løsning av ketonet 2-(3-hexanoylfenoxymethyl)-kinolin (fremstilt fra 3-hexanoylfenol og 2-klormethylkinolin) (6 g, 0,018 mol) i 25 ml tørr THF ble langsomt tilsatt til en svakt tilbakeløpskokende suspensjon av 1,3 g (0,054 mol) natriumhydrid i 75 ml tørr THF inneholdende overskudd av methyljodid (10,3 g, 0,073 mol). Etter at til-
setningen av ketonet var fullført (30 min.), ble reaksjonsblandingen kokt under tilbakeløpskjøling i 4 timer. Etter avkjøling av blandingen til romtemperatur ble overskudd av NaH ødelagt ved tilsetning av methanol. Alt flyktig materiale ble fjernet på rotasjonsfordamper, og residuet ble tatt opp i ethylacetat. Det organiske ekstrakt ble vasket med vann og med saltvann og ble tørket over vannfritt magnesiumsulfat. Etter fjerning av alt løsningsmiddel ble det monomethylerte keton 2-[3-(2-methylhexanoyl)-fenoxymethyl]-kinolin erholdt som en gul olje som veide 8 g.
B. Dette keton (8 g) ble deretter redusert med 1,4 g (0,036 mol) natriumborhydrid i 100 ml ethanol ved romtemperatur i ca. 15 timer. Litt vann og methanol ble tilsatt til reaksjonsblandingen, og deretter ble mesteparten av de flyktige bestanddeler fjernet på rotasjonsfordamper. Residuet ble grundig ekstrahert med ethylacetat, og det organiske lag ble vasket med vann, saltvann og ble deretter tørket over vannfritt MgS04. Alt løsningsmiddel ble fjernet under dannelse av 6 g av en gul olje som ble kromatografert på silicagel under anvendelse av 20% ethylacetat i hexan som elueringsmiddel. Den ønskede monomethylerte alkohol ble erholdt som et gult fast materiale (1,5 g) med sm.p. 64-67°C.
Eksempel 2
2-[ 3-( l- hydroxy- 2, 2- dimethylhexyl)- fenoxymethyl)- kinolin A. Ketonet 2-(3-(2,2-dimethylhexanoyl)-fenoxymethyl)-kinolin (4 g) ble behandlet med 0,9 g natriumborhydrid i 70 ml ethanol ved romtemperatur i 15 timer. Løsningen ble av-kjølt på et isbad, og overskuddet av borhydridet ble ødelagt ved tilsetning av kald fortynnet HCl-løsning dråpevis. Etter at alt av reduksjonsmiddelet var ødelagt, ble pH på løsningen justert til 5-6, hvoretter mesteparten av de flyktige bestanddeler ble fjernet. Residuet ble tatt opp i ethylacetat, og det organiske lag ble vasket med vann, saltvann og ble tørket over MgS04. Den urene alkohol ble isolert ved fjerning av alle løsningsmidler. Den rene alkohol (1,6 g, 114-116°C) ble isolert ved kromatografi på silicagel under anvendelse av 20% ethylacetat i hexan som elueringsmiddel.
B. Fremstilling av 2-( 3-( 2, 2- dimethylhexanoyl)- fenoxy-methylkinolin ( utgangsforbindelse for prosedyre A): En blanding av 12,1 g 2-klormethylkinolin, 15 g 3-(2,2-dimethylhexanoyl)-fenol, 20 g finpulverisert vannfritt kaliumcarbonat og 0,05 g kaliumjodid i 300 ml tørr aceton ble kokt under tilbakeløpskjøling over natten. Suspensjonen ble filtrert, og mesteparten av de flyktige bestanddeler ble fjernet på rotasjonsfordamperen. Residuet ble tatt opp i ethylacetat, ble vasket med 5% NaOH-løsning, vann, saltvann, og ekstraktet ble tørket. Etter fjerning av alt løsningsmiddel ble den urene ether erholdt som en gul olje. Denne olje ble renset på HPLC (Prep. 500, Waters) under anvendelse av 10% ethylacetat i hexan som elueringsmiddel. Det rene materiale ble isolert i et utbytte på 48% (12 g) som en gul olje.
C. Syntese av 3-( 2, 2- dimethylhexanoyl)- fenol
26 g av benzyletheren av den ønskede fenol ble tatt opp i 150 ml methanol, og denne løsning ble hydrogenert i en Parr-apparatur under en hydrogenatmosfære (3,16-3,51 kg/cm<2>) i nærvær av 10 g 10% palladium på carbon. Etter 20-24 timer ble suspensjonen filtrert på celitt, all methanol ble
fjernet under dannelse av den ønskede fenol i 83% utbytte (15,4 g) som en fargeløs væske.
Benzylether-utgangsforbindelsen ble fremstilt ved oxydasjon av 3-(l-hydroxyhexyl)-fenylbenzylether til det tilsvarende keton, etterfulgt av alkylering med methyljodid under dannelse av 2,2-dimethylforbindelsen.
Eksempel 3
2-( 3-( 2-( 2- hvdroxy)- heptyl)- fenoxymethyl)- kinolin- hvdro-klorid
En blanding av 3,1 g 2-klormethylkinolin-hydroklorid og 3 g 2-(3-hydroxyfenyl)-2-heptanol i 300 ml aceton, inneholdende 20 g kaliumcarbonat og 0,2 g kaliumjodid, ble kokt under tilbakeløpskjøling over natten. Reaksjonsblandingen ble avkjølt, og mesteparten av de flyktige bestanddeler ble fjernet på rotasjonsfordamper. Residuet ble tatt opp i ethylacetat og vasket med natriumhydroxydløsning (5%) og saltvann. Det organiske lag ble tørket over magnesiumsulfat, og alt løsningsmiddel ble fjernet under dannelse av det urene produkt (som veide ca. 6 g), som ble renset ved kromatografi (silicagel, 20% ethylacetat i hexan). Den frie base, isolert som en olje, ble oppløst i tørr ether og behandlet med hydrogenkloridgass under dannelse av det rene ønskede salt som et hvitt fast materiale med sm.p. 125°C (spaltning).
Eksempel 4
2-[ 3-( 2- hvdroxy- 2- heptvl)- fenoxymethyl]- kinolin
Til en etherisk løsning av 3,2 g 2-(3-hexanoylfenoxy-methyl ) -kinolin (fremstilt ved oxydasjon av den tilsvarende alkohol med pyridiniumklorkromat i CHC13) ble tilsatt langsomt et overskudd av en 3 M-løsning av 2,5 g methylmag-nesiumbromid (7,0 ml) i ether, og blandingen ble omrørt over natten. En mettet løsning av ammoniumklorid ble dråpevis tilsatt til den godt omrørte reaksjonsblanding inntil løs-ningen ble klar, og et gråhvitt fast materiale koagulerte under dannelse av en hard kake. Væsken ble filtrert, og residuet ble vasket med mer ether. Etherlaget ble fraskilt fra det vandige lag, ble vasket med saltvann og tørket over magnesiumsulfat. Alle flyktige bestanddeler ble fjernet under dannelse av en olje, som ble renset ved kromatografi på silicagel (6% ethylacetat i hexan), under dannelse av den ønskede tertiære alkohol som en klar, fargeløs væske.
Eksempel 5
2-( 3-( 6- fenoxy- 1, 2, 2- trimethyl- l- hydroxyhexyl)- fenoxy-methyl )- kinolin
Til en løsning av 3,6 g av ketonet 2-(3-(6-fenoxy-2,2-dimethylhexanoyl)-fenoxymethyl)-kinolin i 100 ml tørr ether ved 0°C ble dråpevis tilsatt 7,7 ml (23,8 mmol, 3 ekvivalenter) av en etherisk løsning av methylmagnesium-bromid under nitrogenatmosfære. Den klare, orange løsning ble omrørt over natten ved romtemperatur. Til denne løsning ble tilsatt en mettet ammoniumkloridløsning når magnesium-saltene ble utfelt. Etherlaget ble fraskilt, vasket med vann og saltvann og ble deretter tørket over MgSO^ Alle flyktige bestanddeler ble fjernet under dannelse av 4,2 g av det urene produkt. Dette ble renset ved kromatografi på silicagel (25% ethylacetat i hexan, 20% ethylacetat i hexan og til slutt 10% ethylacetat i hexan), under dannelse av 0,9 g av det rene produkt som en gul væske.
Eksempel 6
1- ( 3-( 2- kinolinylmethoxy)- fenyl)- 3- methyl- l, 3- butandiol
En blanding av 10 g (47 mmol) 2-klormethylkinolin-hydroklorid, 6,3 g (52 mmol) 3-hydroxybenzaldehyd, 14,5 g (105 mmol) pulverformet kaliumcarbonat, 1,5 g cesiumcarbonat og 0,7 g natriumjodid i 150 ml tørr aceton ble kokt under tilbakeløpskjøling i 14 timer. Det faste residuum ble filtrert fra, og filtratet ble konsentrert og oppløst i ethylacetat. Den organiske løsning ble vasket suksessivt med 10% NaOH-løsning, vann og saltvann og ble deretter tørket over magnesiumsulfat. Alle flyktige bestanddeler ble fjernet under dannelse av et gult fast materiale som veide 14,8 g. Dette ble omkrystallisert fra hexan-ethanolblanding under dannelse av 11,8 g 4-(3-(2-kinolinylmethoxy)-fenyl-4-hydroxy-2-butanon med sm.p. 116-119°C.
Til en løsning av 2,5 g av det ovenfor angitte hyd-roxyketon i 150 ml tørr THF ble dråpevis tilsatt en etherisk løsning av 17,1 mmol (2,2 ekvivalenter) methylmagnesium-bromid. Reaksjonsblandingen ble omrørt over natten, hvorpå en mettet ammoniumkloridløsning ble tilsatt. De utfelte magnesiumsalter ble filtrert, og filtratet ble konsentrert i vakuum. Det ønskede materiale ble isolert etter rensing ved kromatografi på silicagel under anvendelse av 40% ethylacetat i hexan, som et gult, krystallinsk fast materiale med sm.p. 117-124°C (1,2 g).
Eksempel 7
2- ( 3-( 6, 6, 6- trifluorhexanoyl)- fenoxymethyl)- kinolin
En blanding av 6,8 g (27 mmol) 3-(5,5,5-trifluor-hexanoyl) -f enol og 4,4 g (25 mmol) 2-klormethylkinolin i 75 ml DMSO, inneholdende 14 ml 2 N NaOH, ble omrørt ved romtemperatur over natten (13 timer). Den mørke reaksjonsblanding ble helt over i 200 ml vann, og den vandige løsning ble ekstrahert med 4 x 30 ml ethylacetat. Det organiske ekstrakt ble vasket med 1 N NaOH-løsning, vann og saltvann og ble deretter tørket over magnesiumsulfat. Etter fjerning av alle flyktige bestanddeler ble det erholdt en mørk væske som stivnet ved henstand (7,2 g). Dette faste materiale ble kromatografert (3% ethanol i toluen på silicagel), under dannelse av 4,5 g beigefarget fast materiale med sm.p. 83-4°C, som igjen ble kromatografert (15% aceton i hexan på silicagel), under dannelse av 3,1 g av et hvitt fast materiale med sm.p. 86-87°C. Dette rene materiale ble omkrystallisert fra hexan-aceton (spor) under dannelse av 2,4 g av den ønskede forbindelse som et fargeløst, krystallinsk fast materiale med sm.p. 88-88,5°C (første masse, andre masse sm.p. 87-88°C).
Eksempel 8
2-( 3-( 5, 5, 5- trifluorpentanoyl)- fenoxymethyl)- kinolin
Dette materiale ble syntetisert ved tilbakeløps-kokning av en blanding av 2,6 g (14,5 mmol) 2-klormethylkinolin, 3,7 g (15,9 mmol) 3-(5,5,5-trifluorpentanoyl)-fenol, 6,0 g (43,5 mmol) pulverformet kaliumcarbonat og en katalytisk mengde kaliumjodid (0,1 g) i 50 ml tørr aceton i 14 timer. Etter dette tidsrom ble blandingen filtrert, og filtratet ble konsentrert. Residuet ble oppløst i ether, og etherløsningen ble vasket med saltvann, tørket over mag-nesiumsulf at og ble deretter konsentrert i vakuum. Det rene ønskede keton ble isolert ved kromatografi på silicagel under anvendelse av 20% ethylacetat i hexan som elueringsmiddel. Produktet ble erholdt i et utbytte på 62% (3,4 g), hadde et smeltepunkt på 80-82°C og var et gult fast materiale.
Eksempel 9
2-(3-(6-benzvlo xv- l- hvdroxvhexvl)- fenoxymethyl)- kinolin
3,6 g 2-klormethylkinolin ble kokt under tilbakeløps-kjøling med 4,2 g 3-(6-benzyloxy-l-hydroxyhexyl)-fenol, 8 g pulverformet kaliumcarbonat og 0,2 g kaliumjodid i 150 ml tørr aceton over natten (16 timer). Suspensjonen ble filtrert, filtratet ble konsentrert i vakuum og ble deretter tatt opp i ethylacetat. Denne løsning ble vasket med 5%
NaOH-løsning, vann og saltvann og ble deretter tørket. Alt løsningsmiddel ble fjernet, under dannelse av det urene produkt som ble renset ved kromatografi (silicagel, 30% ethylacetat i hexan). Den rene forbindelse ble oppløst i ether og ble utfelt som hydrokloridsaltet med tørr etherisk HCl-løsning. Det rene salt ble filtrert, vasket med kaldt vann og tørket i vakuum under dannelse av 1,5 g av et brun-
farget pulver med sm.p. 86-89°C.
Eksempel 10
Methyl- 3-( 3-( 2- kinolinylmethoxy)- benzoyl)- propanoat
En blanding av 1,1 g rent 4-(3-(2-kinolinylmethoxy)-fenyl-4-hydroxybutyrat og 6,2 g aktivert mangandioxyd i 25 ml methylenklorid ble omrørt ved romtemperatur. Etter 20 timer ble ikke noe utgangsmateriale påvist ved tynnsjikts-kromatografi. Mangandioxydet ble filtrert gjennom celitt, og methylenkloridløsningen ble konsentrert i vakuum. Residuet ble renset ved kroamtografi på silicagel under anvendelse av 15% ethylacetat i hexan inneholdende 1% eddiksyre som elueringsmiddel. 0,22 g av den ønskede ketoester ble erholdt som et off-white fast materiale med sm.p. 80-81°C.
Eksempel 11
Syntese av 5- fenoxypentylbromid
Til en godt omrørt suspensjon av 15,3 g (0,32 mol) natriumhydrid (50% oljedispersjon) i 500 ml tørr DMF, inneholdende 25 g (0,26 mol) fenol ble dråpevis tilsatt 122,2 g (0,53 mol) 1,5-dibrompentan. Etter at tilsetningen var fullført," ble reaksjonsblandingen omrørt ved 60-70°C i 4 timer. Mesteparten av DMF ble deretter fjernet under redusert trykk, og residuet ble oppløst i 250 ml ethylacetat. Det organiske ekstrakt ble vasket suksessivt med 5% natriumhydroxydløsning, vann og saltvann. Etter tørking av det organiske lag over vannfritt magnesiumsulfat ble alle flyktige bestanddeler fjernet. Den gjenværende gule væske ble deretter destillert under redusert trykk, og det rene produkt ble oppsamlet ved 118-125°C/1 mm som en klar, fargeløs væske (26 g, 40% utbytte).
Syntese av 3-( 6-( fenoxy- l- hydroxyhexyl)- fenol
Til 70 ml forsiktig tilbakeløpskokende tetrahydro-furan, inneholdende 1,1 g (44 mmol) magnesiumringer og en liten jodkrystall, ble dråpevis tilsatt fra en dråpetrakt en løsning av 11,0 g (45 mmol) 5-fenoxypentylbromid i 50 ml tørr THF. Etter 5-7 min. ble Grignård-reaksjonen startet som indikert ved forsvinning av den brune jodfarge. Opp-varmingen ble justert slik at løsningen tilbakeløpskokte forsiktig. Etter at tilsetningen av halogenidet var full-ført (ca. 30 min.), ble den klare løsning kokt under til-bakeløpskjøling i en time. Denne løsning av Grignard-reagenset ble avkjølt til romtemperatur.
En løsning av 5,0 g (41 mmol) 3-hydroxybenzaldehyd i 50 ml tørr THF ble dråpevis tilsatt til en godt omrørt suspensjon av 2,5 g (52 mmol) natriumhydrid (50% oljedispersjon) i 50 ml tørr THF ved romtemperatur. Temperaturen fikk ikke stige over 40°C. Etter at tilsetningen av 3-hydroxybenzaldehyd var fullført (ca. 30 min.), ble den svakt blakke løsning oppvarmet til 45-50°C og ble omrørt i en time ved denne temperatur. Den resulterende klare løsning av natrium-3-formylfenoxyd ble avkjølt til romtemperatur og ble dråpevis tilsatt under anvendelse av en kanyle til den godt omrørte løsning av Grignard-reagenset (hvis fremstilling er beskrevet ovenfor). Et tykt bunnfall ble umiddelbart dannet. Denne blanding ble opprettholdt ved 40-45°C under tilsetning av natriumsaltet. Etter at tilsetningen var fullført (ca. 2 timer), ble reaksjonsblandingen omrørt ved denne temperatur i ytterligere en time og ble deretter avkjølt på et isbad. Overskuddet av reaktive materialer (natriumhydrid, Grignard-reagens etc.) ble ødelagt langsomt ved forsiktig tilsetning av 30 ml methanol, hvorpå 350 ml av en mettet ammoniumkloridløsning ble tilsatt for å oppløse alt fast materiale. Det organiske lag ble fraskilt, og det vandige lag ble ekstrahert med 2 x 75 ml ether. De kombinerte organiske bestanddeler ble vasket med vann, saltvann og ble deretter tørket over vannfritt magnesiumsulfat. Etter tørking av ekstraktet ble alle flyktige bestanddeler fjernet under dannelse av en mørk væske. Denne olje ble triturert med en l:l-blanding av ether og petroleumether (35-55°C), under dannelse av 12 g av et off-white fast materiale. Dette ble krystallisert fra methanol-ethylacetat under dannelse av et hvitt fast materiale med sm.p. 148-9°C.
Syntese av 2-[ 3-( 6- fenoxy- l- hydroxyhexyl)- fenoxymethyl]-kinolin
En blanding av 1,1 g (6,3 mmol) 2-klormethylkinolin, 1,8 g (6,3 mmol) 3-(6-fenoxy-l-hydroxyhexyl)-fenol og 1,74 g (12,6 mmol) finpulverisert, vannfritt kaliumcarbonat i 40 ml aceton, inneholdende katalytiske mengder av finpulverisert, vannfritt cesiumcarbonat (0,4 g, 1,3 mmol) og 0,05 g (0,33 mmol) natriumjodid, ble kokt under tilbakeløpskjøling over natten (15 timer).
Reaksjonsblandingen ble avkjølt til romtemperatur og ble filtrert. Det faste residuum ble grundig vasket med 3 x 15 ml aceton, og alle filtratene ble kombinert. Alle flyktige bestanddeler ble fjernet fra det kombinerte aceton-filtrat, under dannelse av en lysegul viskøs væske som stivnet til et off-white fast materiale ved triturering med en l:l-blanding av ether og petroleumether (35-55°C). Dette faste materiale ble kromatografert på silicagel med 35% ethylacetat i hexan, under dannelse av 1,6 g (60%) av det ønskede produkt som et hvitt, krystallinsk fast materiale, sm.p. 83-84,5 °C.
Den etterfølgende protokoll beskriver en bestemmelse for å påvise inhibitorer for lipoxygenase. Slike inhibitorer er antatt å være i stand til å modulere biosyntesen av leukotriener, en egenskap som er antatt å være anvendbar ved behandling av astma og inflammatoriske sykdomstilstander.
Protokoll for påvisning av inhibitorer av lipoxygenase
En suspensjon av rotteneutrofiler i buffer ble inkubert i 3 min. ved 30°C med [^<4>C]-arachidonsyre (AA) og calciumjonofor A23187. 2 M sitronsyre ble anvendt for å stanse reaksjonen. Etter tilsetning av en spormengde av (<3>H)-5-HETE, sammen med et overskudd av umerket 5-HETE til hvert rør, ble blandingen ekstrahert med kloroform/methanol. Det organiske lag ble vasket med fortynnet syre, og en alikvot ble overført til glassrør og tørket. Residuet ble oppløst i et lite volum kloroform, og en alikvot ble anbrakt på silicagel TLC-ark, som ble fremkalt med et ethylacetat/ isoctan/vann/eddiksyreløsningsmiddelsystem. 5-HETE-flekkene ble synliggjort med jod, ble kuttet ut og anbrakt i scintil-lasjonsampuller for telling. Etter justering for ekstrak-sjonseffekten ble mengden (pmol) av [<14>C] i hvert rør bestemt. Netto pmol av 5-HETE ble erholdt ved subtraksjon av pmol av 5-HETE i rørene inneholdende bare buffer (blind-prøve) fra pmol av 5-HETE i rørene inneholdende buffer og celler (kontroll). Testforbindelsenes evne til å modulere aktiviteten av dette enzym, bestemmes ved en nedsettelse og økning i nettomengden av produsert 5-HETE.
Tabell I viser den nødvendige konsentrasjon for 50% inhibering av 5-lipoxygenase (5-LOX/I50UM) for representative forbindelser fremstilt ifølge foreliggende oppfinnelse.
Claims (2)
1. Analogifremgangsmåte for fremstilling av terapeutisk aktive forbindelser av generell formel
og farmasøytisk akseptable salter derav, hvori
Arx er kinolyl, naftyl eller tetrahydronaftyl; Ar er meta-fenylen eller para-fenylen;idet
Z er en alkylenkjede inneholdende opptil 10 carbonatomer i hovedkjeden og totalt opptil 12 carbonatomer, og med fra 0-2 dobbeltbindinger, og hvor angitte alkylenkjede kan være bundet til Ar gjennom et oxygenatom,
når n' =2 eller 3 er R en substituent uavhengig bundet til et av carbonatomene i Z, utvalgt fra gruppen =0,
0R3, N(R2)2, -CH3 og -C0R4; og
når n' =4 til 7 er R en substituent uavhengig bundet til et carbonatom i Z, utvalgt fra gruppen =0, 0R3, N(R2)2, -CH3, -C0R4 og halogen;
med det forbehold at et omegacarbon av Z ikke er disubstituert med =0 og -0R3, og med det forbehold at når n' er 2 og R er -CH3, er -CH3 ikke beliggende på Z-alkylenkjedens terminale carbonatom;
R2 er H, Ci-Cg-alkyl, fenyl eller benzyl;
R3 er H, C^-Cs-alkyl, Cx-C6-alkanoyl, fenyl, benzyl eller substituert fenyl, hvori substituenten er halogen, Cx-C6-alkyl eller C^-Cg-alkoxy;
R4 er 0R2 eller N(R2)2; n' = 2-7; og
karakterisert ved
kondensering av en forbindelse av formel II med en forbindelse av formel III:
hvori X' er -CH2-Hal og X'' er -0H; eller X' er -0H og X<*>' er -CH2Hal; eller X' er -Hal og X'' er -CH2OH; eller X' er -CH2OH og X" er -Hal; eller X' er -CH2OH og X" er -CH2Hal; eller X' er -CH2-Hal og X" er -CH2OH; eller X' er -0H og X'' er -Hal; eller X' er -Hal og X" er -0H;
under substitusjonsreaksjonsbetingelser for dannelse av en forbindelse av formel I.
2. Analogifremgangsmåte ifølge krav 1 for fremstilling av 2-[3-(1-methyl-1-hydroxyhexyl)fenoxymethyl]kinolin, eller 2-[3-(6-fenoxy-l-hydroxy-l-methylhexyl)fenoxy-methyl]kinolin, karakterisert ved at tilsvarende utgangsmaterialer anvendes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66643084A | 1984-10-30 | 1984-10-30 | |
US73679585A | 1985-05-22 | 1985-05-22 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO854321L NO854321L (no) | 1986-05-02 |
NO174506B true NO174506B (no) | 1994-02-07 |
NO174506C NO174506C (no) | 1994-05-18 |
Family
ID=27099462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO854321A NO174506B (no) | 1984-10-30 | 1985-10-29 | Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0181568A3 (no) |
KR (1) | KR860003226A (no) |
AR (1) | AR243870A1 (no) |
AU (1) | AU595489B2 (no) |
CA (1) | CA1304088C (no) |
DK (1) | DK497885A (no) |
ES (1) | ES8704461A1 (no) |
FI (1) | FI854259L (no) |
NO (1) | NO174506B (no) |
NZ (1) | NZ213986A (no) |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4547509A (en) * | 1983-01-03 | 1985-10-15 | Usv Pharmaceutical Corp. | 5,6,7-Quinoline carbanilates and method of treating ischemic heart disease therewith |
CA1261835A (en) * | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
US4625034A (en) * | 1985-02-04 | 1986-11-25 | Usv Pharmaceutical Corp. | 1,2-Dihydro; 1,2,3,4-tetrahydro; 5,8 dihydro; and 5,6,7,8-tetrahydroquinoline derivatives |
US4839369A (en) * | 1985-04-16 | 1989-06-13 | Rorer Pharmaceutical Corporation | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments |
IE861607L (en) * | 1985-06-18 | 1986-12-18 | Bunce Roger A | 2-substituted quinolines |
US5237070A (en) * | 1985-07-22 | 1993-08-17 | Riker Laboratories, Inc. | Substituted DI-t-butylphenols |
US4716178A (en) * | 1985-07-22 | 1987-12-29 | Riker Laboratories, Inc. | Substituted di-t-butylphenols |
ZA865090B (en) * | 1985-07-22 | 1988-02-24 | Riker Laboratories Inc | Substituted di-t-butylphenols |
US4732978A (en) * | 1985-10-03 | 1988-03-22 | American Home Products Corporation | Novel substituted naphthyloxymethyl quinoline derivatives as anti-inflammatory and antiallergy agents |
EP0219308B1 (en) * | 1985-10-16 | 1991-10-23 | Merck Frosst Canada Inc. | 2-substituted quinolines |
EP0219307A3 (en) * | 1985-10-16 | 1987-10-14 | Merck Frosst Canada Inc. | 2-substituted quinolines |
DE3617183A1 (de) * | 1985-11-16 | 1987-05-27 | Bayer Ag | Substituierte benzylether |
CA1297109C (en) * | 1986-01-17 | 1992-03-10 | Dieter Binder | 2-pyridinyl or 2-quinolinyl-methoxy-thiophene derivatives |
GB2185741B (en) * | 1986-01-27 | 1989-10-25 | American Home Prod | Heterocyclic sulphonamides |
AU6907687A (en) * | 1986-02-18 | 1987-08-20 | Rorer Pharmaceutical Corporation | Composition for treatment of asthmatic conditions using phenoxymethyl quinolines |
DE3632329A1 (de) * | 1986-09-24 | 1988-03-31 | Bayer Ag | Substituierte phenylsulfonamide |
US5202336A (en) * | 1986-09-24 | 1993-04-13 | Bayer Aktiengesellschaft | Antiflammatory quinolin methoxy phenylsulphonamides |
AU613598B2 (en) * | 1986-12-26 | 1991-08-08 | Teijin Limited | Aromatic derivative and preparation method thereof |
AU1549788A (en) * | 1987-03-18 | 1988-10-10 | American Home Products Corporation | Sulfonylcarboxamides |
US5103037A (en) * | 1987-04-06 | 1992-04-07 | Riker Laboratories, Inc. | Substituted di-t-butylphenols |
US5049572A (en) * | 1987-04-06 | 1991-09-17 | Riker Laboratories, Inc. | Substituted di-t-butylphenols and anti-allergic use thereof |
JPS63258854A (ja) * | 1987-04-16 | 1988-10-26 | Mitsubishi Kasei Corp | カルボキシスチレン誘導体およびそれを有効成分とする薬剤 |
DK196688A (da) * | 1987-04-28 | 1988-10-29 | Fujisawa Pharmaceutical Co | Bicykliske forbindelser og fremgangsmaade til fremstilling deraf |
ES2051843T3 (es) * | 1987-05-11 | 1994-07-01 | Ono Pharmaceutical Co | Un proceso para la preparacion de un derivado del acido benzoilaminofenoxibutanico. |
GB8711802D0 (en) * | 1987-05-19 | 1987-06-24 | Fujisawa Pharmaceutical Co | Dithioacetal compounds |
US5066822A (en) * | 1987-11-13 | 1991-11-19 | Riker Laboratories, Inc | Di-t-butylphenols substituted by an alkoxy or benzyloxy group or a benzylthio group |
US4968710A (en) * | 1987-11-13 | 1990-11-06 | Riker Laboratories, Inc. | Substituted di-t-butylphenols and anti-allergic use thereof |
US5204358A (en) * | 1987-11-25 | 1993-04-20 | Merck Frosst Canada, Inc. | Hetaryl styryl quinolines as leukotriene inhibitors |
US5104882A (en) * | 1987-11-25 | 1992-04-14 | Merck Frosst Canada, Inc. | Diarylstrylquinoline diacids and pharmaceutical compositions thereof |
DE3814504A1 (de) * | 1988-04-29 | 1989-11-09 | Bayer Ag | (alpha)-substituierte 4-(chinolin-2-yl-methoxy)phenylessigsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
DE3900261A1 (de) * | 1988-05-31 | 1989-12-07 | Bayer Ag | Substituierte 4-(chinolin-2-yl-methoxy) phenyl-essigsaeure-derivate |
EP0349062A1 (en) * | 1988-06-27 | 1990-01-03 | Merck Frosst Canada Inc. | Quinoline ether alkanoic acid |
NZ229761A (en) * | 1988-07-12 | 1991-10-25 | Ici Pharma | Substituted thiazole derivatives for use as inhibitors of enzyme 5-lipoxygenase; pharmaceutical compositions and preparatory processes |
GB8926981D0 (en) * | 1988-12-23 | 1990-01-17 | Ici Plc | Heterocyclic derivatives |
NZ231735A (en) * | 1988-12-23 | 1992-04-28 | Ici Plc | Alcohol/ether derivatives, preparation and pharmaceutical compositions thereof |
US5214069A (en) * | 1988-12-23 | 1993-05-25 | Imperial Chemical Industries Plc | Alcohol and ether derivatives |
US5219881A (en) * | 1988-12-23 | 1993-06-15 | Imperial Chemical Industries Plc | Cyclic ether derivatives |
IL92620A0 (en) * | 1988-12-23 | 1990-08-31 | Ici Pharma | Cycloalkane derivatives |
GB8927287D0 (en) * | 1988-12-23 | 1990-01-31 | Ici Plc | Cyclic ether derivatives |
US5089495A (en) * | 1989-01-30 | 1992-02-18 | Imperial Chemical Industries Plc | Heterocyclic thiazole derivatives and pharmaceutical compositions comprising said derivatives |
IE66512B1 (en) * | 1989-02-28 | 1996-01-10 | Ici Plc | Heterocyclic ethers as 5-lipoxygenase inhibitors |
US5196419A (en) * | 1989-02-28 | 1993-03-23 | Imperial Chemical Industries Plc | Heterocyclic cyclic ethers |
IL93343A0 (en) * | 1989-02-28 | 1990-11-29 | Ici Plc | Heterocyclic cycloalkanes |
US5217977A (en) * | 1989-02-28 | 1993-06-08 | Imperial Chemical Industries Plc | Heterocyclic cycloalkanes |
US5134148A (en) * | 1989-02-28 | 1992-07-28 | Imperial Chemical Industries Plc | Heterocycles for use as inhibitors of leukotrienes |
IE70521B1 (en) * | 1989-02-28 | 1996-12-11 | Zeneca Pharma Sa | Heterocycles with inhibitory activity of 5-lipoxygenase |
US5202326A (en) * | 1989-02-28 | 1993-04-13 | Imperial Chemical Industries Plc | Heterocyclic ethers |
US5236919A (en) * | 1989-02-28 | 1993-08-17 | Imperial Chemical Industries Plc | Quinoxalinyl derivatives suitable for use in leukotriene mediated disease |
WO1990012006A1 (en) * | 1989-04-07 | 1990-10-18 | Pfizer Inc. | Substituted 1-[3-(heteroarylmethoxy)phenyl]alkanols and related compounds in the treatment of asthma, arthritis and related diseases |
NZ233752A (en) * | 1989-05-24 | 1993-05-26 | Merck Frosst Canada Inc | Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof |
US5214070A (en) * | 1989-07-18 | 1993-05-25 | Imperial Chemical Industries Plc | Diaryl ether cycloalkanes |
IE902113A1 (en) * | 1989-07-18 | 1991-06-19 | Ici Plc | Diaryl ether cyclic ethers |
IE64358B1 (en) * | 1989-07-18 | 1995-07-26 | Ici Plc | Diaryl ether heterocycles |
EP0410661B1 (en) * | 1989-07-26 | 1994-06-15 | Imperial Chemical Industries Plc | Bicyclic derivatives |
US4904674A (en) * | 1989-08-16 | 1990-02-27 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(Benzo[b]thienyl)-2-(thienyl)ethenes and related compounds useful as anti-inflammatory agents |
US5272145A (en) * | 1989-08-22 | 1993-12-21 | Merck Frosst Canada, Inc. | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes |
US5204344A (en) * | 1989-08-22 | 1993-04-20 | Merck Frosst Canada, Inc. | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes |
DE3927930A1 (de) * | 1989-08-24 | 1991-02-28 | Bayer Ag | Cyclisch substituierte (chinolin-2-yl-methoxy)phenyl-essig-saeure-derivate |
DE3927931A1 (de) * | 1989-08-24 | 1991-02-28 | Bayer Ag | Disubstituierte (chinolin-2-yl-methoxy)phenylessigsaeure-derivate |
GB9018134D0 (en) * | 1989-09-29 | 1990-10-03 | Ici Plc | Heterocyclic derivatives |
ATE134630T1 (de) * | 1990-06-21 | 1996-03-15 | Zeneca Ltd | Bizyklische pyran-derivate und ihre verwendung als 5-lipoxygenasehemmer |
AU637500B2 (en) * | 1990-06-21 | 1993-05-27 | Zeneca Limited | Bicyclic heterocyclic compounds |
IE911853A1 (en) * | 1990-06-21 | 1992-01-01 | Ici Plc | Heterocyclene derivatives |
US5254581A (en) * | 1990-06-21 | 1993-10-19 | Imperial Chemical Industries Plc | Pyran derivatives and their use as inhibitors of 5-lipoxygenase |
US4996214A (en) * | 1990-06-28 | 1991-02-26 | Smithkline Beecham Corporation | Quinolinyl substituted phenyl/thioalkanoic acid substituted propionic acids and leucotriene antagonist use thereof |
GB9113137D0 (en) * | 1990-07-13 | 1991-08-07 | Ici Plc | Thioxo heterocycles |
US5272173A (en) * | 1990-11-28 | 1993-12-21 | Imperial Chemical Industries Plc | 5-lipoxygenase inhibitors |
IE913866A1 (en) * | 1990-11-28 | 1992-06-03 | Ici Plc | Aryl derivatives |
IE914005A1 (en) * | 1990-12-14 | 1992-06-17 | Zeneca Ltd | Novel intermediates |
CA2058254A1 (en) * | 1991-01-15 | 1992-07-16 | John Francis Kingston | Benzodioxole derivatives |
AU645159B2 (en) * | 1991-01-17 | 1994-01-06 | Ici Pharma | Sulphonamide derivatives |
US5258399A (en) * | 1991-01-17 | 1993-11-02 | Imperial Chemical Industries Plc | Sulphonamide derivatives |
EP0505122A1 (en) * | 1991-03-21 | 1992-09-23 | Zeneca Limited | Alpha, alpha-dialkylbenzyl derivatives |
GB9214120D0 (en) * | 1991-07-25 | 1992-08-12 | Ici Plc | Therapeutic amides |
US5290798A (en) * | 1991-09-30 | 1994-03-01 | Merck Frosst Canada, Inc. | (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
US5389650A (en) * | 1991-09-30 | 1995-02-14 | Merck Frosst Canada, Inc. | (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
US5190968A (en) * | 1991-09-30 | 1993-03-02 | Merck Frosst Canada, Inc. | (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis |
US5308850A (en) * | 1991-09-30 | 1994-05-03 | Merck Frosst Canada, Inc. | (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
EP0540165A1 (en) * | 1991-10-03 | 1993-05-05 | Zeneca Limited | Alkanoic acid derivatives |
JPH07501550A (ja) * | 1991-12-06 | 1995-02-16 | スミスクライン・ビーチャム・コーポレイション | 複素環式置換ピリジン化合物および使用 |
GB9127252D0 (en) * | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
GB9300894D0 (en) * | 1992-02-07 | 1993-03-10 | Zeneca Ltd | Oxime derivatives |
WO1993016069A1 (en) * | 1992-02-13 | 1993-08-19 | Merck Frosst Canada Inc. | (azaaromaticalkoxy)indoles as inhibitors of leukotriene biosynthesis |
US5506227A (en) * | 1992-04-13 | 1996-04-09 | Merck Frosst Canada, Inc. | Pyridine-substituted benzyl alcohols as leukotriene antagonists |
CA2094465A1 (en) * | 1992-04-23 | 1993-10-24 | Pierre Andre Raymond Bruneau | Cycloalkane derivatives |
CA2095006A1 (en) * | 1992-05-12 | 1993-11-13 | Philip Neil Edwards | Oxime derivatives |
CA2095005A1 (en) * | 1992-05-12 | 1993-11-13 | Philip Neil Edwards | Hydroxylamine derivatives |
IL105558A (en) * | 1992-05-18 | 1998-04-05 | Zeneca Ltd | Tertiary carbinols with channel activity potassium process for their preparation and pharmaceutical preparations containing them |
DE4219765A1 (de) * | 1992-06-17 | 1993-12-23 | Bayer Ag | Substituierte (Benzothiazolyl- und Chinoxalyl-methoxy)phenylessigsäurederivate |
AU4444393A (en) * | 1992-09-01 | 1994-03-10 | Zeneca Limited | Pyrrolidine derivatives |
GB9305295D0 (en) * | 1993-03-15 | 1993-05-05 | Zeneca Ltd | Therapeutic compounds |
US5374635A (en) * | 1993-03-29 | 1994-12-20 | Merck Frosst Canada, Inc. | Furo[3,2-b]pyridines and thieno[3,2-b]pyridines as inhibitors of leukotriene biosynthesis |
GB9310095D0 (en) * | 1993-05-17 | 1993-06-30 | Zeneca Ltd | Therapeutic compounds |
GB9312891D0 (en) * | 1993-06-22 | 1993-08-04 | Boots Co Plc | Therapeutic agents |
CA2214131C (en) * | 1995-03-14 | 2009-06-23 | Novartis Ag | Trisubstituted phenyl derivatives |
JP3909864B2 (ja) * | 1995-07-26 | 2007-04-25 | 小野薬品工業株式会社 | ナフチルオキシ酢酸誘導体およびそれらを有効成分として含有する薬剤 |
US6197993B1 (en) | 1996-07-02 | 2001-03-06 | Ono Pharmaceutical Co., Ltd. | Naphthyloxyacetic acid derivatives and a pharmaceutical composition comprising them as an active ingredient |
TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
US7067539B2 (en) | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
RU2004117907A (ru) | 2001-11-14 | 2006-01-10 | Шеринг Корпорейшн (US) | Лиганды каннабиноидных рецепторов |
MXPA04012704A (es) | 2002-06-19 | 2005-03-23 | Schering Corp | Agonistas de los receptores canabinoides. |
TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
SE0400234D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New compounds, methods for their preparation and use thereof |
CA2677457A1 (en) | 2007-02-06 | 2008-08-14 | Helen Tuvesson Andersson | New compounds, methods for their preparation and use thereof |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE754405A (fr) * | 1969-08-05 | 1971-02-04 | Thomae Gmbh Dr K | Nouveaux beta-aryl-2-aminoalcoxystyrenes |
US3793328A (en) * | 1969-11-03 | 1974-02-19 | Upjohn Co | 8benzoyl 1,2,3,4 tetrahydroquinoline |
GB1357212A (en) * | 1971-06-25 | 1974-06-19 | Labaz | Benzothiophene derivatives and process for preparing the same |
US4053607A (en) * | 1972-04-04 | 1977-10-11 | Beecham Group Limited | Aryloxypyridine for treating hyperglycaemia |
FR2201883B1 (no) * | 1972-10-05 | 1975-10-31 | Roussel Uclaf | |
CH603638A5 (en) * | 1973-03-02 | 1978-08-31 | Ciba Geigy Ag | 2-(piperidino or tetrahydropyrido) benzofurans |
DE2415867A1 (de) * | 1974-04-02 | 1975-10-09 | Merck Patent Gmbh | Phenoxyalkanolderivate und verfahren zu ihrer herstellung |
GB1456323A (en) * | 1974-06-06 | 1976-11-24 | Labaz | Benzothiophenes process for preparing them and pharmaceutical compositions containing the same |
US4024273A (en) * | 1974-06-20 | 1977-05-17 | Smithkline Corporation | Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity |
US3947470A (en) * | 1974-06-20 | 1976-03-30 | Smithkline Corporation | Substituted benzofurans and benzothiophenes |
US3989838A (en) * | 1975-09-22 | 1976-11-02 | Smithkline Corporation | Uricosuric compositions and method of producing uricosuria and hypouricemia |
US4255585A (en) * | 1975-10-22 | 1981-03-10 | Centre European De Recherches Pharmacologique | Benzoheterocyclic derivatives of phenoxyacetic acid |
US4017632A (en) * | 1975-10-22 | 1977-04-12 | Centre European De Recherches Pharmacologiques C.E.R.P.H.A. | Phenoxyacetic acid derivatives |
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
ZA775350B (en) * | 1976-12-23 | 1978-07-26 | Ciba Geigy Ag | Substituted 5-amino-2-pyridinecarboxylic acids |
US4092334A (en) * | 1977-07-28 | 1978-05-30 | International Flavors & Fragrances Inc. | 5-Acyl-2-(furfurylthio)dihydro-2,5-dialkyl-3-[2H]furanones |
EP0002408A1 (fr) * | 1977-11-26 | 1979-06-13 | SOCIETE DE RECHERCHES INDUSTRIELLES S.O.R.I. Société anonyme dite: | Nouveaux composés phénoxy-alcanols substitués, leur procédé de préparation et leur application en thérapeutique |
US4325729A (en) * | 1977-12-13 | 1982-04-20 | Ciba-Geigy Corporation | Herbicidal and plant growth regulating pyridyloxy-phenoxy-propionic acid derivatives |
LU79008A1 (de) * | 1978-02-03 | 1979-09-06 | Byk Gulden Lomberg Chem Fab | W-(n-alkyl-n-benzoyl-amino)-phenylalkansaeuren,ihre verwendung und herstellung sowie sie enthaltende arzneimittel |
US4263040A (en) * | 1978-02-18 | 1981-04-21 | Kumiai Chemical Industry Co., Ltd. | Phenoxyphenoxy unsaturated derivatives and herbicidal composition |
FR2426045A2 (fr) * | 1978-05-19 | 1979-12-14 | Meiji Seika Kaisha | Esters d'acide 5-alkoxy-picoliniques, procede pour leur preparation et composition anti-hypertensive contenant ces esters |
GB2030131B (en) * | 1978-09-12 | 1982-12-22 | Taiyo Pharma Ind | Process for producing 2-(4-(2-thienyl-carbonyl) phenyl) propionic acid |
JPS6033389B2 (ja) * | 1979-02-22 | 1985-08-02 | 日産化学工業株式会社 | 複素環エ−テル系フェノシキ脂肪酸誘導体、その製造法および該誘導体を含有する除草剤 |
US4236912A (en) * | 1979-03-05 | 1980-12-02 | The Dow Chemical Company | Quinolinyloxyphenoxy and quinolyinylthiophenoxy alkanoic acids and derivatives thereof and methods of herbicidal use |
JPS5923309B2 (ja) * | 1979-04-11 | 1984-06-01 | 工業技術院長 | ホルミルスチリル基をもつキノリン誘導体とその製法 |
JPS584712B2 (ja) * | 1979-07-04 | 1983-01-27 | 工業技術院長 | アセタ−ル基をもつ含窒素複素環化合物及びその製造方法 |
AU541697B2 (en) * | 1979-11-19 | 1985-01-17 | Ici Australia Limited | Quinoline derivatives |
USRE31624E (en) * | 1979-11-26 | 1984-07-03 | Forsyth Dental Infirmary For Children | Method of treating inflammation |
JPS56115784A (en) * | 1980-02-15 | 1981-09-11 | Tanabe Seiyaku Co Ltd | Novel pyridinecarboxamide derivative and its preparation |
DE3006351A1 (de) * | 1980-02-20 | 1981-09-17 | Basf Ag, 6700 Ludwigshafen | 2- ((3-amino-2- hydroxy-propoxy)-styryl )-verbindungen |
EP0041476B1 (de) * | 1980-05-31 | 1985-07-24 | Ciba-Geigy Ag | Neue Aryl-Phenyl-Acetylen-Verbindungen |
JPS5732279A (en) * | 1980-08-05 | 1982-02-20 | Mitsubishi Petrochem Co Ltd | Preparation of alpha- 5-benzoyl-2-thienyl propionic acid |
DE3101544A1 (de) * | 1981-01-20 | 1982-08-19 | Hoechst Ag, 6000 Frankfurt | "chinolinoxy-phenoxypropionsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung als herbizide" |
EP0063418B1 (en) * | 1981-04-16 | 1984-10-03 | Imperial Chemical Industries Plc | Indanyloxy- and tetralinyloxy-phenoxypropionic acid derivatives, processes for preparing them, and herbicidal processes and compositions utilising them |
DE3120099A1 (de) * | 1981-05-20 | 1982-12-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Neues arzneimittel mit wirkung auf das zentralnervensystem |
DE3205150A1 (de) * | 1982-02-13 | 1983-08-18 | Celamerck Gmbh & Co Kg, 6507 Ingelheim | Pyridinderivate, ihre herstellung und verwendung |
CH651034A5 (de) * | 1982-05-12 | 1985-08-30 | Hoffmann La Roche | Chroman-, thiochroman- oder 1,2,3,4-tetrahydrochinolinderivate und ihre verwendung als arzneimittel-wirkstoffe. |
US4522647A (en) * | 1982-07-30 | 1985-06-11 | Zoecon Corporation | Substituted phenoxyalkanediones and their herbicidal method of use |
US4520199A (en) * | 1982-08-13 | 1985-05-28 | Zoecon Corporation | Alkoxy substituted phenoxy alkanoic acid esters |
US4469872A (en) * | 1982-08-20 | 1984-09-04 | Zoecon Corporation | Substituted pyridyloxyphenoxyhydroxyketones |
JPS5973579A (ja) * | 1982-10-19 | 1984-04-25 | Kotobuki Seiyaku Kk | ベンゾフラン又はベンゾチオフェン誘導体,この化合物を有効成分とする尿酸***剤及びその製造方法 |
US4464533A (en) * | 1982-11-08 | 1984-08-07 | Ppg Industries, Inc. | Herbicidally active quinoline or quinoxaline benzoate derivatives |
IE56702B1 (en) * | 1982-12-01 | 1991-11-06 | Usv Pharma Corp | Antiinflammatory antiallergic compounds |
JPS59152891A (ja) * | 1983-02-18 | 1984-08-31 | Yamada Kagaku Kogyo Kk | 発色性記録材料 |
ZA848416B (en) * | 1983-11-10 | 1986-06-25 | Dow Chemical Co | Fluorophenoxy compounds,herbicidal compositions and methods |
JPS60110887A (ja) * | 1983-11-18 | 1985-06-17 | Shiyouno Tamie | α−アルキル化酢酸誘導体の製造方法 |
JPS60172964A (ja) * | 1984-02-15 | 1985-09-06 | Tanabe Seiyaku Co Ltd | 桂皮酸誘導体及びその製法 |
HU195492B (en) * | 1984-07-27 | 1988-05-30 | Boehringer Biochemia Srl | Process for producing 2-substituted thiazolidine derivatives with antitussive and mucus regulating action and pharmaceuticals comprising these compounds as active ingredient |
DE3431004A1 (de) * | 1984-08-23 | 1986-03-06 | Hoechst Ag, 6230 Frankfurt | Neue 3-pyridylverbindungen und verfahren zu ihrer herstellung |
US4625034A (en) * | 1985-02-04 | 1986-11-25 | Usv Pharmaceutical Corp. | 1,2-Dihydro; 1,2,3,4-tetrahydro; 5,8 dihydro; and 5,6,7,8-tetrahydroquinoline derivatives |
DE3508903A1 (de) * | 1985-03-13 | 1986-09-18 | Hoechst Ag, 6230 Frankfurt | Neue 3-pyridylmethylnaphtylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US4839369A (en) * | 1985-04-16 | 1989-06-13 | Rorer Pharmaceutical Corporation | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments |
IE861607L (en) * | 1985-06-18 | 1986-12-18 | Bunce Roger A | 2-substituted quinolines |
EP0206772A3 (en) * | 1985-06-20 | 1988-05-11 | E.I. Du Pont De Nemours And Company | Herbicidal aryloxybenzeneacetic acid derivatives |
US4732978A (en) * | 1985-10-03 | 1988-03-22 | American Home Products Corporation | Novel substituted naphthyloxymethyl quinoline derivatives as anti-inflammatory and antiallergy agents |
EP0219307A3 (en) * | 1985-10-16 | 1987-10-14 | Merck Frosst Canada Inc. | 2-substituted quinolines |
-
1985
- 1985-10-29 NO NO854321A patent/NO174506B/no unknown
- 1985-10-29 NZ NZ213986A patent/NZ213986A/xx unknown
- 1985-10-30 KR KR1019850008032A patent/KR860003226A/ko not_active Application Discontinuation
- 1985-10-30 AR AR85302113A patent/AR243870A1/es active
- 1985-10-30 DK DK497885A patent/DK497885A/da not_active Application Discontinuation
- 1985-10-30 FI FI854259A patent/FI854259L/fi not_active IP Right Cessation
- 1985-10-30 EP EP85113830A patent/EP0181568A3/en not_active Withdrawn
- 1985-10-30 AU AU49264/85A patent/AU595489B2/en not_active Ceased
- 1985-10-30 CA CA000494211A patent/CA1304088C/en not_active Expired - Lifetime
- 1985-10-30 ES ES549012A patent/ES8704461A1/es not_active Expired
Also Published As
Publication number | Publication date |
---|---|
AU4926485A (en) | 1986-05-08 |
EP0181568A2 (en) | 1986-05-21 |
FI854259A0 (fi) | 1985-10-30 |
DK497885A (da) | 1986-05-01 |
ES549012A0 (es) | 1987-04-16 |
DK497885D0 (da) | 1985-10-30 |
CA1304088C (en) | 1992-06-23 |
NO174506C (no) | 1994-05-18 |
FI854259L (fi) | 1986-05-01 |
KR860003226A (ko) | 1986-05-21 |
AR243870A1 (es) | 1993-09-30 |
EP0181568A3 (en) | 1989-04-26 |
AU595489B2 (en) | 1990-04-05 |
NZ213986A (en) | 1989-07-27 |
NO854321L (no) | 1986-05-02 |
ES8704461A1 (es) | 1987-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO174506B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser | |
Boekelheide et al. | Syntheses of pyrrocolines unsubstituted in the five-membered ring1 | |
US3931205A (en) | Substituted alkanoic acids and derivatives | |
US4259338A (en) | Benzofuranyl-tetrahydropyridines and -piperidines, their acid addition salts and antidepressant preparations thereof | |
NO760993L (no) | ||
NO145657B (no) | Analogifremgangsmaate for fremstilling av fysiologisk aktive alkenderivater. | |
NO141800B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive benzomorfaner | |
Sundberg et al. | o-Styrylnitrene route to 2-substituted indoles. Pyrolysis of o-azidostyrenes | |
NO137440B (no) | Analogifremgangsm}te for fremstilling av terapeutisk aktive pleuromutiliner | |
EP0242167B1 (en) | Heterocyclic carboxamides | |
NO163552B (no) | Sammensatt understell. | |
HU185133B (en) | Process for producing 1-hydroxy-octahydro-benzo-bracket-c-bracket closed-quinolines and derivatives | |
NO142865B (no) | Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive karbazoler | |
NO803453L (no) | Fremgangsmaate ved fremstilling av piperidylbenzimidazolonderivater | |
NO163597B (no) | Styreinnretning for et ett-eller tosporet kjoeretoey. | |
JPS584781A (ja) | テトラヒドロピリジン及びピペリジン誘導体の製法 | |
CS207619B2 (en) | Method of making the new derivatives of 5,11-dihydro-6h-pyrido 2,3-b 1,4 benzodiazepin-6-on | |
NO172643B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive benzopyranolderivater | |
GB2056435A (en) | Novel Tetrahydropyridine and Piperidine Substituted Benzofuranes and Related Compounds | |
CA2179634C (en) | 4-arylisoindole analgesics | |
NO121212B (no) | ||
US3316272A (en) | Heterocyclic derivatives of triphenyl-ethylenes, triphenylethanes and triphenylethanols | |
US5175297A (en) | Methyl-quinoline derivatives as mefloquin intermediates and process for preparation thereof | |
NO149353B (no) | Fremgangsmaate ved fremstilling av 6-klor-alfa-metylkarbazol-2-eddiksyre | |
SU1017167A3 (ru) | Способ получени @ -5-ацетамидо-4,5,6,7-тетрагидро-2н-бензо/с/пиррола |